308 related articles for article (PubMed ID: 28229892)
1. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
Cadavid D; Balcer L; Galetta S; Aktas O; Ziemssen T; Vanopdenbosch L; Frederiksen J; Skeen M; Jaffe GJ; Butzkueven H; Ziemssen F; Massacesi L; Chai Y; Xu L; Freeman S;
Lancet Neurol; 2017 Mar; 16(3):189-199. PubMed ID: 28229892
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.
Klistorner A; Chai Y; Leocani L; Albrecht P; Aktas O; Butzkueven H; Ziemssen T; Ziemssen F; Frederiksen J; Xu L; Cadavid D;
CNS Drugs; 2018 Dec; 32(12):1159-1171. PubMed ID: 30267385
[TBL] [Abstract][Full Text] [Related]
3. Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab.
Petrillo J; Balcer L; Galetta S; Chai Y; Xu L; Cadavid D
J Neuroophthalmol; 2019 Jun; 39(2):153-160. PubMed ID: 30095536
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D; Mellion M; Hupperts R; Edwards KR; Calabresi PA; Drulović J; Giovannoni G; Hartung HP; Arnold DL; Fisher E; Rudick R; Mi S; Chai Y; Li J; Zhang Y; Cheng W; Xu L; Zhu B; Green SM; Chang I; Deykin A; Sheikh SI;
Lancet Neurol; 2019 Sep; 18(9):845-856. PubMed ID: 31285147
[TBL] [Abstract][Full Text] [Related]
5. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.
Lagrèze WA; Küchlin S; Ihorst G; Grotejohann B; Beisse F; Volkmann M; Heinrich SP; Albrecht P; Ungewiss J; Wörner M; Hug MJ; Wolf S; Diem R;
Lancet Neurol; 2021 Dec; 20(12):991-1000. PubMed ID: 34800417
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
[TBL] [Abstract][Full Text] [Related]
11. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
[TBL] [Abstract][Full Text] [Related]
15. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Raftopoulos R; Hickman SJ; Toosy A; Sharrack B; Mallik S; Paling D; Altmann DR; Yiannakas MC; Malladi P; Sheridan R; Sarrigiannis PG; Hoggard N; Koltzenburg M; Gandini Wheeler-Kingshott CA; Schmierer K; Giovannoni G; Miller DH; Kapoor R
Lancet Neurol; 2016 Mar; 15(3):259-69. PubMed ID: 26822749
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.
Sühs KW; Hein K; Sättler MB; Görlitz A; Ciupka C; Scholz K; Käsmann-Kellner B; Papanagiotou P; Schäffler N; Restemeyer C; Bittersohl D; Hassenstein A; Seitz B; Reith W; Fassbender K; Hilgers R; Heesen C; Bähr M; Diem R
Ann Neurol; 2012 Aug; 72(2):199-210. PubMed ID: 22926853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
